A Look At Intuitive Surgical (ISRG) Valuation As Hedge Funds React To Procedure Growth And da Vinci 5 Rollout

Intuitive Surgical (ISRG) has moved back into focus after large hedge funds sharply increased their positions, as the company reported strong procedure volumes, recurring revenue strength, and the ongoing rollout of its da Vinci 5 system.

See our latest analysis for Intuitive Surgical.

The latest share price of US$450.62 leaves Intuitive Surgical with a 30 day share price return of a 4.56% decline and a year to date share price return of a 19.82% decline. The 3 year total shareholder return of 68.76% and 5 year total shareholder return of 66.37% show that longer term holders have seen stronger gains even as recent sentiment has cooled following the da Vinci 5 launch headlines and brisk procedure growth.

If you are weighing Intuitive Surgical against other opportunities in medical robotics and automation, it can help to see what else is moving in this theme via the 33 robotics and automation stocks

So with Intuitive Surgical posting annual revenue of US$10.06b and net income of US$2.86b, yet seeing its shares fall sharply this year, are you looking at a potential overlooked entry point, or is the market already accounting for future growth in its current pricing?

Most Popular Narrative: 15.4% Undervalued

At a last close of $450.62 against a narrative fair value of $532.46, the current price sits meaningfully below what this framework considers reasonable.

Over the next 5 years I calculate with (actual values from 18.01.26, price/shr at 533 USD): Revenue Growth p.a.: 12% (Currently at 14.7%), we saw the peak of revenue growth with nearly 15%. Now even 12% is sporty, but with the “abo like” revenues from spare parts and software licences, based on a still growing bases of installed systems, realistic. Profit Margin: 30% (currently at 28.6%), because spare parts in general have more margin than system sales, and the sales out of spare parts is still growing. Future PE: 50 (currently at 69), the high PEs are typical for fast growers, but over time the PE will go down. I see for next 5 years 50, in 10 years it could come down to 40. Interest rate: 6.77% (same as current), which leads to an FV of 533 USD, means ISRG trades with 0.5% at fair value.

Read the complete narrative.

Curious what sits behind that fair value figure and return estimate? The narrative leans heavily on compound top line growth, rising margins and a premium future earnings multiple. The mix of recurring revenue, assumed profitability step up and a still elevated valuation bar are the real levers here.

Result: Fair Value of $532.46 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this depends on assumptions about sustained procedure growth and premium P/E levels. These could be challenged if hospital budgets tighten or new competitors gain traction.

Find out about the key risks to this Intuitive Surgical narrative.

Another View: High P/E Signals A Rich Price

While the community narrative sees Intuitive Surgical as 15.4% undervalued, the current P/E of 56x tells a different story. That is well above the US Medical Equipment industry at 26.2x, the peer average at 30.7x, and the 35.5x fair ratio our model suggests the market could move toward. For you, that gap raises a simple question: is this quality already more than priced in?

To see how this richer earnings multiple compares in more detail, including how the numbers look against the fair ratio and peers, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly split between valuation risk and long term growth potential, it makes sense to look at the facts yourself and move quickly while views are still forming. You can start with the 3 key rewards.

Looking for more investment ideas?

If Intuitive Surgical has your attention, this is the moment to widen your watchlist with other focused ideas that match the way you like to invest.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com